Earnings Roundup
Biogen Idec Grows Revenue 7% in 'High Quality' 1Q Miss
Biogen Idec Inc. added 1,900 Tysabri (natalizumab) patients during the first three months of 2012, increasing revenues from the multiple sclerosis drug by 14 percent year over year to $286 million, on global in-market sales of $399 million.